MediciNova has been granted a patent for higher dosage oral formulations of ibudilast in tablet or capsule form. The pharmaceutical composition includes specific percentages of ibudilast, lactose, microcrystalline cellulose, hypromellose, magnesium stearate, and colloidal silicon dioxide, with a dissolution profile ensuring release within 2 hours. GlobalData’s report on MediciNova gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights MediciNova Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MediciNova, Peptide pharmacophores was a key innovation area identified from patents. MediciNova's grant share as of February 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11865214B2) discloses a pharmaceutical composition containing ibudilast, lactose, microcrystalline cellulose, hypromellose, magnesium stearate, and colloidal silicon dioxide. The composition, in the form of a tablet or capsule, is designed to release at least 12% of ibudilast within 2 hours in simulated gastric fluid. Additionally, the tablet may have a coating comprising polyvinyl alcohol, plasticizer, and pigment to enhance its properties.

Furthermore, the patent claims specify the percentages of each component in the composition, ranging from 3% to 15% ibudilast, 30% to 40% lactose, 30% to 40% microcrystalline cellulose, 15% to 25% hypromellose, 0.2% to 0.8% magnesium stearate, and 0.5% to 5% colloidal silicon dioxide. The dissolution profile of the tablet or capsule is crucial, with at least 90% of ibudilast being released within 24 hours under specific testing conditions. The composition may contain ibudilast ranging from 10 mg to 100 mg, with lactose specified as lactose monohydrate in certain instances. The patent also covers variations such as tablets with coatings, different excipients, and the composition being in the form of a capsule.

To know more about GlobalData’s detailed insights on MediciNova, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies